191 related articles for article (PubMed ID: 8572663)
1. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
Ann Neurol; 1996 Jan; 39(1):29-36. PubMed ID: 8572663
[TBL] [Abstract][Full Text] [Related]
2. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
[TBL] [Abstract][Full Text] [Related]
3. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
4. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548
[TBL] [Abstract][Full Text] [Related]
5. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
Shoulson I
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
[TBL] [Abstract][Full Text] [Related]
6. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
7. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
8. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
Marras C; Lang AE; Eberly SW; Oakes D; Fahn S; Schwid SR; Hyson C; Shoulson I;
Mov Disord; 2009 Dec; 24(16):2370-8. PubMed ID: 19908310
[TBL] [Abstract][Full Text] [Related]
9. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
Parkinson Study Group
N Engl J Med; 1993 Jan; 328(3):176-83. PubMed ID: 8417384
[TBL] [Abstract][Full Text] [Related]
10. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Shoulson I
Eur Neurol; 1992; 32 Suppl 1():46-53. PubMed ID: 1425820
[TBL] [Abstract][Full Text] [Related]
11. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group.
Shoulson I
Acta Neurol Scand Suppl; 1989; 126():171-5. PubMed ID: 2515723
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
14. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1989 Oct; 46(10):1052-60. PubMed ID: 2508608
[TBL] [Abstract][Full Text] [Related]
15. Effect of deprenyl on the progression of disability in early Parkinson's disease.
Parkinson Study Group
N Engl J Med; 1989 Nov; 321(20):1364-71. PubMed ID: 2509910
[TBL] [Abstract][Full Text] [Related]
16. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
17. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
Marras C; McDermott MP; Rochon PA; Tanner CM; Naglie G; Rudolph A; Lang AE;
Neurology; 2005 Jan; 64(1):87-93. PubMed ID: 15642909
[TBL] [Abstract][Full Text] [Related]
18. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
Rinne UK
J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
[TBL] [Abstract][Full Text] [Related]
19. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group.
Shults CW
Acta Neurol Scand Suppl; 1993; 146():36-42. PubMed ID: 8333252
[TBL] [Abstract][Full Text] [Related]
20. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
